# US 2017/0283769 A1 · Modified Cells Evoking Reduced Immunogenic Responses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0283769 A1
- Document ID: US20170283769A1
- Status: Published application
- Kind: A1
- Application number: 15/616,787
- Filed: 2017-06-07
- Published: 2017-10-05
- Earliest claimed: 2015-01-17
- Assignees: Zhejiang University
- Applicants: Zhejiang University
- Inventors: Lei Xiao; Haide Chen; Chun Cui; Yang Li; Di Cui
- Web page: https://patentgrep.com/patent/US20170283769A1

## CPC

- C12N 5/0606: {Pluripotent embryonic cells, e.g. embryonic stem cells [ES] (embryonic germ cells C12N5/0611, induced pluripotent stem cells C12N5/0696)}
- A61K 35/545: Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
- A61K 40/10: characterised by the cell type used
- A61K 40/42: Cancer antigens
- C12N 5/0603: {Embryonic cells (production of embryos, nuclear transfer A01K67/027); Embryoid bodies}
- C12N 5/0639: {Dendritic cells, e.g. Langherhans cells in the epidermis}
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- C12N 2510/00: Genetically modified cells
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure describes composition, methods, and systems associated with a genetically modified stem cell. The modified stem cell includes a reduced amount of Major Histocompatibility Complex II (MHC II) as compared to a corresponding wild-type cell. Further, the modified cell has decreased immunogenicity as compared to the corresponding wild-type cell.

## Claims

### Claim 1

A modified cell comprising a disruption of MHC class II transactivator (CIITA) gene, wherein the modified cell is a modified stem cell or a cell derived from the modified stem cell.

### Claim 2 (depends on 1)

The modified cell of claim 1, wherein the MHC II is Human Leukocyte antigen II (HLA-II).

### Claim 3 (depends on 1)

The modified cell of claim 1, wherein the modified stem cell comprises at least one of a totipotent stem cell, a pluripotent stem cell, an embryonic stem cell, an induced pluripotent stem cell, or a multipotent stem cell.

### Claim 4 (depends on 1)

The modified cell of claim 1, wherein the modified stem cell comprises a human embryonic stem cell.

### Claim 5 (depends on 1)

The modified cell of claim 1, wherein a karyotype of the modified cell is the same as a karyotype of the corresponding wild-type cell.

### Claim 6 (depends on 1)

The modified cell of claim 1, wherein a level of pluripotency of the modified cell is substantially the same as a level of pluripotency of the corresponding wild-type cell.

### Claim 7 (depends on 1)

The modified cell of claim 1, wherein the disruption of CIITA gene comprises a disruption of one or more exons of CIITA gene having the nucleic acid sequence of SEQ ID NO: 46.

### Claim 8 (depends on 7)

The modified cell of claim 7, wherein the modified cell comprises at least one of the nucleic acid sequence of SEQ ID NOs: 47-58.

### Claim 9 (depends on 1)

The modified cell of claim 1, wherein the modified cell has decreased immunogenicity as compared to the corresponding wild-type cell.

### Claim 10 (depends on 9)

The modified cell of claim 9, wherein the decreased immunogenicity comprises a decreased level of inflammatory responses induced by the modified cell as compared to the corresponding wild-type cell.

### Claim 11

A method of reducing T cell responses to presentation of a cell, the method comprising Introducing a disruption of MHC class II transactivator (CIITA) gene of the cell to obtain a modified cell, wherein the cell is a stem cell or a cell derived from the stem cell, the disruption of CIITA of the cell produces a reduced T cell responses to the presentation of the modified cell as compared to a wild-type cell.

### Claim 12 (depends on 11)

The method cell of claim 11, wherein the MHC II is HLA-II.

### Claim 13 (depends on 11)

The method cell of claim 11, wherein the stem cell comprises at least one of a totipotent stem cell, a pluripotent stem cell, an embryonic stem cell, an induced pluripotent stem cell, or a multipotent stem cell.

### Claim 14 (depends on 11)

The method cell of claim 11, wherein the stem cell comprises a human embryonic stem cell.

### Claim 15 (depends on 11)

The method cell of claim 11, wherein the T cell is a CD4+ T-cell.

### Claim 16 (depends on 11)

The method cell of claim 11, wherein a level of pluripotency of the modified cell is substantially the same as a level of pluripotency of the cell.

### Claim 17 (depends on 11)

The method cell of claim 11, wherein the disruption of CIITA gene comprises a disruption of one or more exons of CIITA gene having the nucleic acid sequence of SEQ ID NO: 46.

### Claim 18 (depends on 17)

The method cell of claim 17, wherein the modified cell comprises one of the nucleic acid sequence of SEQ ID NOs: 47-58.
